{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:31:02Z","timestamp":1792024262630,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Endocrinology & Metabolism"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.tem.2024.02.007","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T16:09:41Z","timestamp":1709222981000},"page":"697-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":804,"title":["Current status and future trends of the global burden of MASLD"],"prefix":"10.1016","volume":"35","author":[{"given":"Lei","family":"Miao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Targher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-2631","authenticated-orcid":false,"given":"Ming-Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tem.2024.02.007_bb0005","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0010","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","article-title":"The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease","volume":"14","author":"Eslam","year":"2020","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.tem.2024.02.007_bb0015","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S2468-1253(22)00127-3","article-title":"Promoting the term MAFLD: China in action","volume":"7","author":"Zhang","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0020","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2023","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0025","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"80","author":"Song","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0030","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"Ciardullo","year":"2023","journal-title":"Liver Int."},{"key":"10.1016\/j.tem.2024.02.007_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15856","article-title":"Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults","author":"Song","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.tem.2024.02.007_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2022.1047129","article-title":"Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: a systematic analysis of the global burden of disease study 2019","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Nutr."},{"key":"10.1016\/j.tem.2024.02.007_bb0045","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.tem.2024.02.007_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-036663","article-title":"Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990\u20132017: a population-based observational study","volume":"10","author":"Ge","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.tem.2024.02.007_bb0055","doi-asserted-by":"crossref","first-page":"849","DOI":"10.21037\/hbsn-21-352","article-title":"Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future","volume":"10","author":"Wang","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.tem.2024.02.007_bb0060","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","author":"Younossi","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","article-title":"Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver","volume":"10","author":"Kaya","year":"2022","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0075","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","author":"Zhou","year":"2023","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.tem.2024.02.007_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415489","article-title":"Non-alcoholic fatty liver disease (NAFLD) pathogenesis and natural products for prevention and treatment","volume":"23","author":"Guo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2024.02.007_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0090","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis \u2013 aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tem.2024.02.007_bb0100","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type2 diabetes: an update","volume":"13","author":"Lee","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"10.1016\/j.tem.2024.02.007_bb0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.7861\/clinmedicine.18-3-245","article-title":"Non-alcoholic fatty liver disease","volume":"18","author":"Maurice","year":"2018","journal-title":"Clin. Med. (Lond.)"},{"key":"10.1016\/j.tem.2024.02.007_bb0110","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s00535-017-1415-1","article-title":"Current and future pharmacological therapies for NAFLD\/NASH","volume":"53","author":"Sumida","year":"2018","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.tem.2024.02.007_bb0115","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3390\/diagnostics10110912","article-title":"Complications of non-alcoholic fatty liver disease in extrahepatic organs","volume":"10","author":"Tomeno","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.tem.2024.02.007_bb0120","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.3390\/ijerph16183415","article-title":"NAFLD and extra-hepatic comorbidities: current evidence on a multi-organ metabolic syndrome","volume":"16","author":"Rosato","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.tem.2024.02.007_bb0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/a-1862-9088","article-title":"Nonalcoholic fatty liver disease: current global burden","volume":"42","author":"El-Kassas","year":"2022","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.tem.2024.02.007_bb0130","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2024.02.007_bb0135","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep4.1599","article-title":"The growing burden of disability related to nonalcoholic fatty liver disease: data from the Global Burden of Disease 2007\u20132017","volume":"4","author":"Paik","year":"2020","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tem.2024.02.007_bb0140","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from Global Burden of Disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0145","article-title":"Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","author":"Younossi","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tem.2024.02.007_bb0150","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.tem.2024.02.007_bb0155","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease \u2013 meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2024.02.007_bb0160","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tem.2024.02.007_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1037211","article-title":"Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies","volume":"13","author":"Albhaisi","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tem.2024.02.007_bb0175","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/nu15010066","article-title":"The FIB-4 index predicts the development of liver-related events, extrahepatic cancers, and coronary vascular disease in patients with NAFLD","volume":"15","author":"Kamada","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.tem.2024.02.007_bb0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41575-023-00846-4","article-title":"Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease","volume":"21","author":"Feng","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.tem.2024.02.007_bb0190","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S2468-1253(19)30349-8","article-title":"The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Sepanlou","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0195","article-title":"NAFLD and MAFLD as emerging causes of HCC: a populational study","volume":"3","author":"Myers","year":"2021","journal-title":"JHEP Rep."},{"key":"10.1016\/j.tem.2024.02.007_bb0200","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1097\/CM9.0000000000001888","article-title":"Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma","volume":"134","author":"Rios","year":"2021","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.tem.2024.02.007_bb0205","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac167","article-title":"Prognosis after hepatic resection of patients with hepatocellular carcinoma related to non-alcoholic fatty liver disease: meta-analysis","volume":"7","author":"Su","year":"2023","journal-title":"BJS Open"},{"key":"10.1016\/j.tem.2024.02.007_bb0210","doi-asserted-by":"crossref","first-page":"945","DOI":"10.21037\/hbsn-23-539","article-title":"Metabolic dysfunction-associated fatty liver disease and hepatocellular carcinoma: present and future","volume":"12","author":"Gao","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.tem.2024.02.007_bb0215","first-page":"S239","article-title":"Non-alcoholic steatohepatitis (NASH) has become the most common indication for liver transplantation among candidates with hepatocellular carcinoma in the United States","volume":"78","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2024.02.007_bb0220","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.tem.2024.02.007_bb0225","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.3748\/wjg.v20.i28.9330","article-title":"Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations","volume":"20","author":"Mili\u0107","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.tem.2024.02.007_bb0230","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.dld.2021.12.002","article-title":"Association of metabolic health phenotypes, obesity, and hepatocellular carcinoma risk","volume":"54","author":"Nasereldin","year":"2022","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.tem.2024.02.007_bb0235","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0140-6736(10)62037-5","article-title":"National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9\u00b71 million participants","volume":"377","author":"Finucane","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tem.2024.02.007_bb0240","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.3390\/jcm11175144","article-title":"Nonalcoholic fatty liver disease and its complex relation with type 2 diabetes mellitus \u2013 from prevalence to diagnostic approach and treatment strategies","volume":"11","author":"Diaconu","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tem.2024.02.007_bb0245","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.tem.2024.02.007_bb0250","doi-asserted-by":"crossref","first-page":"541","DOI":"10.51821\/84.4.003","article-title":"The prevalence of disorders of the gut\u2013brain axis in type 2 diabetes mellitus patients with metabolic dysfunction-associated fatty liver disease: an observational study","volume":"84","author":"Van Nieuwenhove","year":"2021","journal-title":"Acta Gastroenterol. Belg."},{"key":"10.1016\/j.tem.2024.02.007_bb0255","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8429847","article-title":"Metabolic (dysfunction)-associated fatty liver disease in Chinese patients with type 2 diabetes from a subcenter of the National Metabolic Management Center","volume":"2022","author":"Guan","year":"2022","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.tem.2024.02.007_bb0260","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2024.02.007_bb0265","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1058995","article-title":"Identifying advanced MAFLD in a cohort of T2DM and clinical features","volume":"14","author":"Sanchez-Bao","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tem.2024.02.007_bb0270","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gut.2011.242016","article-title":"Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease","volume":"60","author":"Wong","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.tem.2024.02.007_bb0275","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5009\/gnl210167","article-title":"Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease","volume":"16","author":"Moon","year":"2022","journal-title":"Gut Liver"},{"key":"10.1016\/j.tem.2024.02.007_bb0280","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.tem.2024.02.007_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol. Metab."},{"key":"10.1016\/j.tem.2024.02.007_bb0290","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12933-022-01697-0","article-title":"Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention","volume":"21","author":"Zhou","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.tem.2024.02.007_bb0295","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0300","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110563","article-title":"Metabolic dysfunction-associated fatty liver disease can significantly increase the risk of chronic kidney disease in adults with type 2 diabetes","volume":"197","author":"Wei","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.tem.2024.02.007_bb0310","article-title":"Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.tem.2024.02.007_bb0315","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/CM9.0000000000001263","article-title":"MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy","volume":"134","author":"Xian","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.tem.2024.02.007_bb0320","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41581-021-00519-y","article-title":"Association of metabolic dysfunction-associated fatty liver disease with kidney disease","volume":"18","author":"Wang","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.tem.2024.02.007_bb0325","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/hbsn-22-421","article-title":"An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease","volume":"12","author":"Sun","year":"2023","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"10.1016\/j.tem.2024.02.007_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113320","article-title":"Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications","volume":"23","author":"Lonardo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2024.02.007_bb0335","doi-asserted-by":"crossref","DOI":"10.1136\/egastro-2023-100005","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: a systematic review and meta-analysis","volume":"1","author":"Zhou","year":"2023","journal-title":"eGastroenterology"},{"key":"10.1016\/j.tem.2024.02.007_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med."},{"key":"10.1016\/j.tem.2024.02.007_bb0345","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/gutjnl-2020-323082","article-title":"Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.tem.2024.02.007_bb0350","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3390\/ijms17050717","article-title":"Non-alcoholic fatty liver disease and extra-hepatic cancers","volume":"17","author":"Sanna","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tem.2024.02.007_bb0355","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.jhep.2019.08.018","article-title":"The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity \u2013 a longitudinal cohort study","volume":"71","author":"Allen","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0360","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s00535-023-02021-7","article-title":"MAFLD: an optimal framework for understanding liver cancer phenotypes","volume":"58","author":"Crane","year":"2023","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.tem.2024.02.007_bb0365","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.3390\/curroncol29070356","article-title":"Non-alcoholic fatty liver disease and extrahepatic cancers: a wolf in sheep's clothing?","volume":"29","author":"Mitsala","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.tem.2024.02.007_bb0370","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/j.1440-1746.2009.06117.x","article-title":"Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps","volume":"25","author":"Hwang","year":"2010","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0375","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2796.2011.02377.x","article-title":"Nonalcoholic fatty liver disease: an independent risk factor for colorectal neoplasia","volume":"270","author":"Stadlmayr","year":"2011","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.tem.2024.02.007_bb0380","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000479","article-title":"Nonalcoholic fatty liver disease: a negative risk factor for colorectal cancer prognosis","volume":"94","author":"You","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.tem.2024.02.007_bb0385","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2024.02.007_bb0390","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2017.08.001","article-title":"Clinical and economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"22","author":"Younossi","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.tem.2024.02.007_bb0395","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013620","article-title":"Disparities between research attention and burden in liver diseases: implications on uneven advances in pharmacological therapies in Europe and the USA","volume":"7","author":"Ndugga","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.tem.2024.02.007_bb0400","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/poh2.8","article-title":"Portal hypertension in NAFLD: challenges and perspectives","volume":"1","author":"Miao","year":"2022","journal-title":"Portal Hypertens. Cirrhosis"},{"key":"10.1016\/j.tem.2024.02.007_bb0405","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1053\/j.gastro.2011.06.061","article-title":"Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States","volume":"141","author":"Charlton","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tem.2024.02.007_bb0410","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl19069","article-title":"Extrahepatic manifestations of nonalcoholic fatty liver disease","volume":"14","author":"Li","year":"2020","journal-title":"Gut Liver"},{"key":"10.1016\/j.tem.2024.02.007_bb0415","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0420","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003100","article-title":"Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies","volume":"17","author":"Jarvis","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.tem.2024.02.007_bb0425","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0430","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","article-title":"A global survey of physicians knowledge about nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0435","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jhep.2021.10.025","article-title":"The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?","volume":"76","author":"Lazarus","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0440","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/HEP.0000000000000361","article-title":"The global fatty liver disease Sustainable Development Goal country score for 195 countries and territories","volume":"78","author":"Lazarus","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2024.02.007_bb0445","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jhep.2019.08.027","article-title":"A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe","volume":"72","author":"Lazarus","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0450","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.cgh.2019.01.027","article-title":"Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis","volume":"17","author":"Pelusi","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0455","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0460","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jhep.2022.10.034","article-title":"Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores","volume":"78","author":"Sanyal","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0465","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/HEP.0000000000000351","article-title":"Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes","volume":"78","author":"Pennisi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.tem.2024.02.007_bb0470","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic Landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tem.2024.02.007_bb0475","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3350\/cmh.2022.0015","article-title":"Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: a narrative review","volume":"28","author":"Miao","year":"2022","journal-title":"Clin. Mol. Hepatol."},{"key":"10.1016\/j.tem.2024.02.007_bb0480","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s12325-021-01690-1","article-title":"Perspectives on precision medicine approaches to NAFLD diagnosis and management","volume":"38","author":"Lonardo","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.tem.2024.02.007_bb0485","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/hep.32560","article-title":"NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status","volume":"76","author":"Kim","year":"2022","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/j.tem.2024.02.007_bb0490","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology (Baltimore, Md.)"}],"container-title":["Trends in Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276024000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043276024000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:34:46Z","timestamp":1731497686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043276024000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":98,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1043276024000365"],"URL":"https:\/\/doi.org\/10.1016\/j.tem.2024.02.007","relation":{},"ISSN":["1043-2760"],"issn-type":[{"value":"1043-2760","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status and future trends of the global burden of MASLD","name":"articletitle","label":"Article Title"},{"value":"Trends in Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tem.2024.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}